Pediatric oncology drug development and dosage optimization
S. Y. Amy Cheung, Justin L. Hay, Yu-Wei Lin, Rik de Greef, Julie Bullock · 2024
Read Pediatric oncology drug development and dosage optimization by S. Y. Amy Cheung, Justin L. Hay, Yu-Wei Lin, Rik de Greef, Julie Bullock (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10860405.txt.
Description
Cheung and co-authors wrote this review of cancer drug development for children, dated 2023 in its head. Cancer drug trials in adults are small, open-label studies that raise the dose step by step in tiny groups. Trials in children usually start much later in the program.
The child's first dose is often based on the adult phase 2 dose, scaled for body size. Child studies are small too, since the diseases are rarer in the young. Dose is raised or lowered until the team finds the highest dose patients can bear that still shows useful action. Those steps often follow fixed rules. The authors note that rule-based steps ignore much of the data on how the drug moves through the body and acts on it. The review argues for smarter dose choices that use all of that data.
Catalog record
| CREATOR | S. Y. Amy Cheung, Justin L. Hay, Yu-Wei Lin, Rik de Greef, Julie Bullock |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |